Aqua Bio Technology ASA engages in developing and commercializing active ingredients for use in skin care products in Norway. More Details
+ 1 more risk
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Aqua Bio Technology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ABT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ABT exceeded the Norwegian Chemicals industry which returned 7.5% over the past year.
Return vs Market: ABT exceeded the Norwegian Market which returned -13.5% over the past year.
Price Volatility Vs. Market
How volatile is Aqua Bio Technology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDid Aqua Bio Technology ASA (OB:ABT) Insiders Buy Up More Shares?
3 months ago | Simply Wall StWho Has Been Buying Aqua Bio Technology ASA (OB:ABT) Shares?
4 months ago | Simply Wall StDid You Manage To Avoid Aqua Bio Technology's (OB:ABT) Devastating 85% Share Price Drop?
Is Aqua Bio Technology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ABT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ABT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ABT is unprofitable, so we can't compare its PE Ratio to the XE Chemicals industry average.
PE vs Market: ABT is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ABT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ABT is overvalued based on its PB Ratio (111x) compared to the XE Chemicals industry average (1.7x).
How is Aqua Bio Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Materials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aqua Bio Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Aqua Bio Technology's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Aqua Bio Technology competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Materials industry.
How has Aqua Bio Technology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABT is currently unprofitable.
Growing Profit Margin: ABT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ABT is unprofitable, and losses have increased over the past 5 years at a rate of 54.9% per year.
Accelerating Growth: Unable to compare ABT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABT is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-10%).
Return on Equity
High ROE: ABT has a negative Return on Equity (-1194.42%), as it is currently unprofitable.
How is Aqua Bio Technology's financial position?
Financial Position Analysis
Short Term Liabilities: ABT's short term assets (NOK3.7M) exceed its short term liabilities (NOK3.1M).
Long Term Liabilities: ABT has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ABT's debt to equity ratio (145.9%) is considered high.
Reducing Debt: ABT's debt to equity ratio has increased from 7.9% to 145.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABT has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ABT is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.
What is Aqua Bio Technology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: ABT is not paying a notable dividend for the Norwegian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABT's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Espen Kvale (44 yo)
Mr. Espen Østhagen Kvale serves as the Chief Executive Officer at Aqua Bio Technology ASA since July 1, 2020 and served as its Interim Chief Executive Officer from January 2019 to July 1, 2020. He served a ...
CEO Compensation Analysis
Compensation vs Market: Espen's total compensation ($USD0.00) is below average for companies of similar size in the Norwegian market ($USD371.70K).
Compensation vs Earnings: Espen's compensation has been consistent with company performance over the past year.
|Director||1.67yrs||no data||no data|
|Chairman of the Board||4.67yrs||kr285.00k||5.44% |
Experienced Board: ABT's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23%.
Aqua Bio Technology ASA's company bio, employee growth, exchange listings and data sources
- Name: Aqua Bio Technology ASA
- Ticker: ABT
- Exchange: OB
- Founded: 2000
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: kr122.271m
- Shares outstanding: 18.39m
- Website: https://www.aquabiotechnology.com
- Aqua Bio Technology ASA
- Fornebuveien 37
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ABT||OB (Oslo Bors)||Yes||Ordinary Shares||NO||NOK||Jan 2008|
|0I8C||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||NOK||Jan 2008|
|ABTO||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||NOK||Jan 2008|
Aqua Bio Technology ASA engages in developing and commercializing active ingredients for use in skin care products in Norway. It offers Aquabeautine XL, a proprietary ingredient; and Spirulysat, an antioxi ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/27 03:42|
|End of Day Share Price||2020/09/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.